Aspiring AryanCel
Taylor Hill is my mommy
- Joined
- Nov 29, 2025
- Posts
- 21
- Reputation
- 38
A lot of people reduce “bone growth” to just denser bones or assume every bone-active compound does the same thing. That’s not how it works.
Different compounds affect different parts of bone biology — some mainly prevent bone loss, some can stimulate new bone formation, and some are only interesting because of experimental growth signalling, not because they’re actually proven for visible skeletal change.
These are more interesting than standard anti-resorptives because they are anabolic, meaning they can actually stimulate new bone formation rather than just slow breakdown.
What they do:
They activate the PTH1 receptor, which increases osteoblast activity when used in the right pattern. That means they can increase bone mass, improve bone turnover in a more constructive way, and in some cases produce more meaningful structural change than drugs that only preserve bone.
Why people care:
This is one of the few drug classes that makes people think of actual bone gain, not just “better DEXA numbers.” It is still not magic, but it is much more biologically plausible for real new bone formation than something like denosumab alone.
Important distinction:
More bone formation does not automatically mean visible outward widening. You can gain bone mass without getting dramatic external skeletal change.
This is related but worth separating because PTHrP is more tied to developmental bone signalling, growth plate regulation, and skeletal maturation.
What it does:
PTHrP helps regulate how cartilage and bone cells behave during growth, especially in areas like the growth plate. It is part of the signalling network that influences timing of maturation and how quickly growth-related tissues move toward senescence or closure.
Why it matters:
This is where things start becoming more relevant to people interested in height, longitudinal growth, or more developmental aspects of skeletal biology rather than just adult osteoporosis-style bone strengthening.
Reality check:
This is also where people start overinterpreting things. A pathway being important in growth biology does not mean you can just hijack it and get clean, predictable skeletal growth in humans.
This is probably the most emotionally charged one because a lot of people associate it with frame growth, craniofacial changes, or bone width.
What it does:
Growth hormone increases IGF-1 signalling, which affects bone formation, soft tissue growth, cartilage activity, and overall anabolic signalling. It does not only affect bone — it affects a lot of tissue systems.
Why people talk about it:
Compared to purely anti-resorptive drugs, HGH is more logically connected to things like periosteal apposition (growth on the outer bone surface), tissue enlargement, and broader structural changes.
The catch:
That doesn’t mean the results are neat or aesthetic. More growth signalling can mean thicker, heavier, or more irregular tissue changes rather than “idealized” facial or skeletal improvement. More tissue is not automatically better tissue.
This is one of the most important pathways in bone biology, and also one of the most overhyped.
What it does:
Wnt/β-catenin signalling plays a major role in osteoblast differentiation, bone formation, and skeletal signalling more broadly. If you activate this pathway, you are pushing one of the core systems involved in building and maintaining bone.
Why it gets attention:
Because it is one of the few pathways that sounds genuinely relevant to real structural bone change, not just bone preservation.
Why it’s risky:
This pathway is powerful, but it is also involved in a lot more than just bone. Once people start talking about strong Wnt activation, they are no longer talking about a clean “bone-only” effect. They are talking about interfering with a major regulatory pathway involved in cell growth, differentiation, and tissue behaviour across the body.
So yes, it is one of the most interesting pathways — but also one of the most dangerous.
This is where a lot of the mouse-study compounds come in. These compounds are usually interesting because they attempt to increase bone signalling through mechanisms like:
What they’re trying to do:
The goal is usually to push the skeleton toward a more growth-permissive / anabolic state, sometimes even with effects on growth plate biology in animal models.
Why people get hyped:
Because this is where you start seeing phrases like:
And yes, that sounds amazing.
But here’s the problem:
Mouse growth data gets massively oversold. A compound doing something dramatic in adolescent mice does not mean it translates cleanly to adult humans, facial bones, or “looksmaxxing” goals.
A lot of these compounds are mechanistically interesting, but nowhere near “proven aesthetic skeletal enhancer.”
The Main Distinction People Need to Understand
A lot of confusion comes from mixing up these four things:
My Current Conclusion
Most “bone drugs” are not really bone growth drugs in the way people on these forums want them to be.
A lot of them are better at preserving, reinforcing, or rebuilding internally than causing dramatic visible external skeletal change.
If outward change happens at all, it is probably more likely to come from a combination of:
So the real truth is:
Not all bone-active compounds are equal.
Some improve density, some improve mass, some affect signalling, and only a very small number are even theoretically relevant to visible skeletal growth.
Bhais, formatting might be cooked cause i wrote this on notes but itll have to do.
Also it took me awhile to write this forum so hope it’s helpful.
Different compounds affect different parts of bone biology — some mainly prevent bone loss, some can stimulate new bone formation, and some are only interesting because of experimental growth signalling, not because they’re actually proven for visible skeletal change.
- PTH Analogs — Teriparatide / Abaloparatide
These are more interesting than standard anti-resorptives because they are anabolic, meaning they can actually stimulate new bone formation rather than just slow breakdown.
What they do:
They activate the PTH1 receptor, which increases osteoblast activity when used in the right pattern. That means they can increase bone mass, improve bone turnover in a more constructive way, and in some cases produce more meaningful structural change than drugs that only preserve bone.
Why people care:
This is one of the few drug classes that makes people think of actual bone gain, not just “better DEXA numbers.” It is still not magic, but it is much more biologically plausible for real new bone formation than something like denosumab alone.
Important distinction:
More bone formation does not automatically mean visible outward widening. You can gain bone mass without getting dramatic external skeletal change.
- PTHrP Signalling
This is related but worth separating because PTHrP is more tied to developmental bone signalling, growth plate regulation, and skeletal maturation.
What it does:
PTHrP helps regulate how cartilage and bone cells behave during growth, especially in areas like the growth plate. It is part of the signalling network that influences timing of maturation and how quickly growth-related tissues move toward senescence or closure.
Why it matters:
This is where things start becoming more relevant to people interested in height, longitudinal growth, or more developmental aspects of skeletal biology rather than just adult osteoporosis-style bone strengthening.
Reality check:
This is also where people start overinterpreting things. A pathway being important in growth biology does not mean you can just hijack it and get clean, predictable skeletal growth in humans.
- HGH / IGF-1
This is probably the most emotionally charged one because a lot of people associate it with frame growth, craniofacial changes, or bone width.
What it does:
Growth hormone increases IGF-1 signalling, which affects bone formation, soft tissue growth, cartilage activity, and overall anabolic signalling. It does not only affect bone — it affects a lot of tissue systems.
Why people talk about it:
Compared to purely anti-resorptive drugs, HGH is more logically connected to things like periosteal apposition (growth on the outer bone surface), tissue enlargement, and broader structural changes.
The catch:
That doesn’t mean the results are neat or aesthetic. More growth signalling can mean thicker, heavier, or more irregular tissue changes rather than “idealized” facial or skeletal improvement. More tissue is not automatically better tissue.
- Wnt / β-catenin Pathway
This is one of the most important pathways in bone biology, and also one of the most overhyped.
What it does:
Wnt/β-catenin signalling plays a major role in osteoblast differentiation, bone formation, and skeletal signalling more broadly. If you activate this pathway, you are pushing one of the core systems involved in building and maintaining bone.
Why it gets attention:
Because it is one of the few pathways that sounds genuinely relevant to real structural bone change, not just bone preservation.
Why it’s risky:
This pathway is powerful, but it is also involved in a lot more than just bone. Once people start talking about strong Wnt activation, they are no longer talking about a clean “bone-only” effect. They are talking about interfering with a major regulatory pathway involved in cell growth, differentiation, and tissue behaviour across the body.
So yes, it is one of the most interesting pathways — but also one of the most dangerous.
- Experimental Dual Wnt Activators / Research Compounds
This is where a lot of the mouse-study compounds come in. These compounds are usually interesting because they attempt to increase bone signalling through mechanisms like:
- CXXC5–DVL inhibition
- GSK3β inhibition
- broader Wnt pathway activation
What they’re trying to do:
The goal is usually to push the skeleton toward a more growth-permissive / anabolic state, sometimes even with effects on growth plate biology in animal models.
Why people get hyped:
Because this is where you start seeing phrases like:
- “delayed growth plate senescence”
- “increased longitudinal bone growth”
- “enhanced bone mass in mice”
And yes, that sounds amazing.
But here’s the problem:
Mouse growth data gets massively oversold. A compound doing something dramatic in adolescent mice does not mean it translates cleanly to adult humans, facial bones, or “looksmaxxing” goals.
A lot of these compounds are mechanistically interesting, but nowhere near “proven aesthetic skeletal enhancer.”
The Main Distinction People Need to Understand
A lot of confusion comes from mixing up these four things:
- Bone mineral density
More mineral packed into bone. Can make bone stronger. Does not automatically mean visible growth. - Bone mass
More total bone tissue. More meaningful than density alone. Still doesn’t always mean obvious external change. - Periosteal apposition
Actual growth on the outer surface of bone. This is what most people are really asking about when they say “bone widening.” - Longitudinal growth
Actual increase in bone length, usually dependent on growth plate biology. Much harder to influence, especially once skeletal maturity is advanced.
My Current Conclusion
Most “bone drugs” are not really bone growth drugs in the way people on these forums want them to be.
A lot of them are better at preserving, reinforcing, or rebuilding internally than causing dramatic visible external skeletal change.
If outward change happens at all, it is probably more likely to come from a combination of:
- anabolic signalling
- mechanical stimulus
- growth responsiveness
- age / maturity
- genetics
- and how the tissue actually responds over time
So the real truth is:
Not all bone-active compounds are equal.
Some improve density, some improve mass, some affect signalling, and only a very small number are even theoretically relevant to visible skeletal growth.
Bhais, formatting might be cooked cause i wrote this on notes but itll have to do.
Also it took me awhile to write this forum so hope it’s helpful.
